• Genetic TherapyEnrolling

  Study of ARCT-032 in adults with cystic fibrosis who are not on CFTR modulator therapy. , protocol number Arcturus ARCT-032-02

  This study will test the safety, tolerability and effectiveness of ARCT-032, a nebulized therapy intended to deliver a new, correct copy of CFTR messenger RNA (mRNA) to cells.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    8

  • Length of Participation:

    20 weeks

• Restore CFTR ProteinEnrolling

  Phase 3 study of VX-121/tezacaftor/deutivacaftor in children ages 2 to 5 with cystic fibrosis , protocol number Vertex VX21-121-105 Cohort B2

  This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability and how the body processes the drug VX-121/tezacaftor/deutivacaftor in participants with at least one triple-combination responsive CF mutation. 

  • Age:

    2 Years to 5 Years

  • Mutation(s):

    Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    8

  • Length of Participation:

    32 weeks

• Anti-InfectiveEnrolling

  Study to evaluate inhaled RSP-1502 in adults with cystic fibrosis and Pseudomonas aeruginosa , protocol number Respirion RESPIR-102

  This study will look at the safety of inhaled RSP-1502, a drug intended to treat infections in the lung. RSP-1502, which includes the antibiotic tobramycin, will be compared to tobramycin alone. The study will measure the drug's safety, how well it works, and how the body processes it. Four doses of RSP-1502 will be tested to find the best dose. 

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    4

  • Length of Participation:

    28 days

• ObservationalEnrolling

  An observational study monitoring health changes in people with cystic fibrosis ages 6 and older who start taking vanzacaftor/tezacaftor/deutivacaftor after discontinuing use of elexacaftor/tezacaftor/ivacaftor (RETRIAL). , protocol number RETRIAL

  This observational study will monitor the mental health and liver function of people with cystic fibrosis who had experienced mental health symptoms or liver issues while taking elexacaftor/tezacaftor/ivacaftor (ETI) and have started taking vanzacaftor/tezacaftor/deutivacaftor (VTD).

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    2

  • Length of Participation:

    15 months

• OtherEnrolling

  A study to evaluate the insulin-only Bionic Pancreas in people with cystic fibrosis 14 years of age or older who have cystic fibrosis-related diabetes (CFRD) , protocol number Bionic Pancreas CFRD IOBP V 1.0.

  This study will evaluate the effectiveness and safety of using the insulin-only Bionic Pancreas (BP) system compared to using one’s usual insulin delivery method.

  • Age:

    14 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    7 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.